shabza1

Studies have demonstrated that semaglutide not only effectively controls blood glucose but also significantly reduces the risk of major adverse cardiovascular events (MACE) in individuals with type 2 diabetes. The landmark SUSTAIN and PIONEER trials have showcased its remarkable ability to lower the risk of heart attacks, strokes, and cardiovascular mortality.